NYT: Duke Univ. scandal shed light on flawed multi-gene cancer test

The New York Times has a story today that paints a damning portrait of life sciences researchers and companies that are rushing toward market with molecular tests for cancer before the tests have proven their value in helping fight cancer--sometimes with tragic consequences for patients who put their faith in the diagnostics. The story's unfortunate poster child of the problem is a Duke University multi-gene test for predicting effective drugs against cancer that was eventually found to be ineffective. Statisticians at MD Anderson Cancer Center found the bugs in the Duke test, but the flaws didn't gain wide attention until it came to light last year that one of the Duke cancer researchers behind the test falsified his resume. Story

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.